Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York
Mandate

Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York

October 17, 2019 Capital Markets and Public M&A

Vinge has advised Aprea Therapeutics, Inc. and its subsidiary Aprea Therapeutics AB in connection with its listing on Nasdaq, New York.

The initial public offering price was set to $15 and the biopharmaceutical company sold 6.5 million shares in the IPO to raise $97.75 million. Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing cancer therapeutics.

 
Vinge’s team has primarily consisted of Kristina Ekberg, Charlotte Levin, Maria Schultzberg, Anna Thoms and Stina Bengtsson.

Related

Vinge advises Stockwik Förvaltning in conjunction with the acquisition of Labino

 Vinge has advised Stockwik Förvaltning in connection with its acquisition of Labino, a world-leading Swedish manufacturer of industrial UV light fixtures.
December 19, 2025

Vinge advises Revivo Group in conjunction with the acquisition of Nordisk Ytbehandling

 Vinge has advised Revivo Group in connection with the acquisition of Nordisk Ytbehandling, a well-established contracting company based in Nyköping specialising in blasting as well as anti-corrosion and fire protection painting, with a solid customer base within the industrial and infrastructure sectors.
December 19, 2025

Vinge advises on the sale of NCS Colour

 Vinge has advised Sobro and other owners in conjunction with Helix Kapital becoming a new owner partner in NCS Colour, together with the management team.
December 19, 2025